In nearly 50% of prostate cancers, the PI3K-Akt survival pathway has been shown to be constitutively upregulated because of loss of function and/or mutation of tumor suppressor PTEN, which functions as a negative regulator of PI3K through its lipid phosphatase activity [48]. This evidence concerns the gene PTEN and prostate carcinoma.